- Outset Medical ( NASDAQ: OM ) rose 10.26% pre market after it sees Q4 revenue to be ~$31.5 million vs. consensus of $29.14M, a 13% increase compared to $27.8 million in the third quarter of 2022.
- Revenue for 2022 is expected to be ~$115 million, a 12% increase compared to $102.6 million in 2021 vs. consensus of $112.26M.
- The company continues to expect its full-year 2022 non-GAAP gross margin will be in the mid-teens, as previously indicated.
- Outlook: It expects 2023 revenue to be between $140 million to $150 million, growing approximately 22% to 30% over expected revenue for 2022 vs. consensus of $145.45M.
- Non-GAAP gross margin is expected to expand to approximately 20% for the full year 2023 and exit the year in the mid-20% range for the fourth quarter of 2023.
For further details see:
Outset Medical stocks soars after sees Q4 revenue $31.5M above estimates; issues FY23 guidance